Management of hormone-sensitive metastatic prostate cancer. Update of hormonal therapy

Cancer Practice

Volumn 5, Issue 4, 1997, Pages 258-263

  Figg, William D ^a   Feuer, Jonathan A ^a   Bauer, Kenneth S ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANTIANDROGEN; BICALUTAMIDE; CISPLATIN; DIETHYLSTILBESTROL; ESTROGEN; FINASTERIDE; FLUTAMIDE; GLUCOCORTICOID; GONADORELIN DERIVATIVE; GOSERELIN; HORMONE; HYDROCORTISONE; IMIDAZOLE DERIVATIVE; KETOCONAZOLE; LEUPRORELIN; LIAROZOLE; MEGESTROL ACETATE; NILUTAMIDE; STEROID 5ALPHA REDUCTASE INHIBITOR; SURAMIN;

ADRENAL DISEASE; ASTHENIA; CANCER HORMONE THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRY SKIN; EDEMA; ESTROGEN THERAPY; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HUMAN; HYPOTHYROIDISM; LIVER TOXICITY; MALE; METASTASIS; ORCHIECTOMY; ORTHOSTATIC HYPOTENSION; PROSTATE CANCER; RASH; REVIEW; SOMNOLENCE; THROMBOEMBOLISM;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 0031427593     PISSN: 10654704     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Parker SL, Tong T, Dolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997; 47:5-27.
2. Gerber GS, Chodak GW. Treatment of early stage prostate cancer. In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS, eds. Comprehensive Textbook of Genitourinary Oncology. Baltimore: Williams and Wilkins; 1996:734-740.
3. Middleman MN, Lush RM, Figg WD. The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate. Pharmacotherapy 1996; 16:376-381.
4. Labrie F, Belanger A, Simard J, Labrie C, Dupont A. Combination therapy for prostate cancer: endocrine and biologic basis of its choice as new standard first-line therapy. Cancer Supp 1993; 71(suppl 3):1059-1067.
5. Goldspiel BR, Kolesar JM, Kuhn JG. Prostate cancer. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach. Stamford, Connecticut: Appleton & Lange; 1997:2539-25-58.
6. Huggins C, Hodges GV: Studies on prostate cancer: I. The effect of castration, estrogen and androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1:293-295.
7. Stone NN. Hormonal approaches in the treatment of bony metastases. Oncology 1994; 8(suppl):9-14.
8. Byar DP. The Veterans Administration Cooperative Urologie Research Group's studies of cancer of the prostate. Cancer 1973; 32:1126-1130.
9. Bailar JC, Byar DP. The Veterans Administration Cooperative Urologie Research Group: Estrogen treatment for cancer of the prostate: early results with 3 doses of diethylstilbestrol and placebo. Cancer 1970; 26:257-261.
10. Blackard CE, Doe RP, Mellinger GT, Byar DP. Incidence of cardiovascular disease and death in patients receiving diethylstilbestrol for carcinoma of the prostate. Cancer 1970; 26:249-256.
11. The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 1984; 311:1281-1286.
12. Labrie F. Intracrinology; the basis for the rational design of endocrine therapy at all stages of prostate cancer. Mol Cell Endocrinol 1991; 78:C113-C118.
13. Labrie F, Dupont A, Bélanger A, Cusan L, Lacourcière Y, Monfette G, et al. New hormonal therapy in prostate carcinoma: combined treatment with an LH-RH agonist and antiandrogen. Clin Invest Med 1982; 5:267-275.
14. Crawford ED, Eisenberger MA, McCleod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ. A controlled trial of leuprolide with and without flutamide in prostate carcinoma. N Engl J Med 1989; 321:419-424.
15. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995; 346:265-269.
16. Crawford ED, Hussain M, DeAntoni EP, et al. Southwestern Oncology Group strategies in prostate carcinoma. Semin Surg Oncol 1995; 11:60-64.
17. Neri R, Monahan MD, Meyer JG, Alfonson BA, Tabachnick IA. Biological studies on an antiandrogen (SH-714). Eur J Pharmacol 1967; 1:438-444.
18. Crawford ED, Eisenberger, MA, McLeod DG, Blumenstein BA. Comparison of bilateral orchiectomy with or without flutamide for the treatment of patients (PTS) with stage D2 adenocarcinoma of the prostate (CaP): results of NCI intergroup study 0105 (SWOG and ECOG). J Urol 1997; 157:336. Abstract 1311.
19. Scher HI, Kelley WK: Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993; 11:1566-1572.
20. Figg WD, Sartor O, Cooper MR, et al. Prostate specific antigen decline following discontinuation of flutamide in patients with stage D2 prostate cancer. Am J Med 1995; 98:412-414.
21. Small EJ, Srinivas S. The antiandrogen withdrawal syndrome: experience in a large cohort of unselected advanced prostate cancer patients. Cancer 1995; 76:1428-1434.
22. Herrada J, Dieringer P, Logothetis CJ. Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal. J Urol 1996; 155:620-623.
23. Sartor O, Cooper M, Weinberger M, et al. Surprising activity of flutamide withdrawal when combined with aminoglutethimide in treatment of "hormone-refractory" prostate cancer. J Natl Cancer Inst 1994; 86:222-227.
24. Dupont A, Gomez JL, Cusan L, Koutsilieris M, Labrie F. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 1993; 150:908-913.
25. Figg WD, Dawson NA, Middleman MN, Brawley O, Lush RM, Senderowicz A, Steinberg SM, Tompkins A, Reed E, Sartor O. Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with "hormone-refractory" prostate cancer. Acta Oncol 1996; 35:763-765.
26. Dawson NA, Cooper MR, Figg WD, et al. Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer 1995; 76:453-462.
27. Kubota Y, Nakada T, Imai K, Yamanaka H, Sakai H, Saito Y, Tomaru Y, Kitamura K, Sugano O, Sasagawa I. Chemo-endocrine therapy in patients with stage D2 prostate cancer. Prostate 1995; 26:50-54.
28. Dawson NA, Figg WD, Cooper MR, et al. Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer. J Clin Oncol 1997; 15:1470-1477.
29. Ornstein DK, Rao GS, Johnson B, Charlton ET, Andriole GL. Combined finasterid and flutamide therapy in men with advanced prostate cancer. Urology 1996; 48:901-905.
30. Fleshner NE, Trachtenberg J. Treatment of advanced prostate cancer with the combination of finasteride plus flutamide: early results. Eur Urol 1993; 24(suppl 2):106-112.
31. Oliver RTD, Williams G, Paris AMI, Blandy JP. Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer. Urology 1997; 49:79-82.
32. Goldenberg SL, Bruchovsky N, Cleave ME, et al. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report, 1995. Urology 1995; 45:839-845.
33. Higano CS, Ellis W, Russell K, Lange PH. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology 1996; 48:800-804.
34. Drago JR, Santen RJ, Lipton A, et al. Clinical effect of aminoglutethimide, medical adrenalectomy in treatment of 43 patients with advanced prostatic carcinoma. Cancer 1984; 53:1447-1150.
35. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for asymptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14:1756.
36. Geller LJ, Zahyna D, Scheuer S, Tchekmedyian NS. High dose megestrol acetate in advanced prostate cancer: a phase II trial. Proc Am Soc Clin Oncol 1993; 12:A800.
37. Dawson NA, Conaway M, Winer EP, et al. A randomized study comparing standard versus moderately high dose megestrol acetate in advanced prostate cancer: a Cancer and Leukemia Group B study. Proc Am Soc Clin Oncol 1995; 14:A618.
38. Pont A, Williams PL, Azhar S, et al. Ketoconazole bocks testosterone synthesis. Arch Intern Meet 1982; 142:2137.
39. Dixon SC, Zalles A, Lush RM, Reed E, Figg WD. Activity of ketoconazole and gallium as single agents or in combination in the prostate cancer cell line PC-3. Cancer Lett 1997; 113:111-116.
40. Seidmon EJ, Trump DL, Kreis W, Hall SW, Kurman MR, Ouyang SP, Wu J, Kremer AB. Phase I/II dose-escalation study of liarozole in patients with stage D, hormone-refractory carcinoma of the prostate. Ann Surg Oncol 1995; 2:550-556.
41. Hussain M, Wolf M, Marshall E, Crawford ED, Eisenberger M. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol 1994; 12:1868-1875.
42. Taylor CD, Elson P, Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 1993; 11:2167-2172.